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PENILAIAN TERAZOSIN UNTUK RAW ATAN PENY AKIT 
PROSTATITIS KRONIK 
ABSTRAK 
\Valaupun prostatitis kronik merupakan jenis penyakit prostatitis yang paling biasa, 
tctapi ia paling kurang difahami. Sehingga kini, masih belum terdapat rawatan yang 
dibukti berkesan untuk penyakit ini. Oleh yang demikian, kajian ini bertujuan untuk 
menilai keberkesanan terazosin, suatu drug penghalang reseptor a1 untuk rawatan 
prostatitis kronik. 
Sebelum kajian di atas dilaksanakan, indeks prostatitis kronik iaitu, "National Institutes 
of Health - Chronic Prostatitis Symptom Index" (NIH-CPS!), yang disyorkan oleh 
National Institutes of Health Amerika Syarikat untuk digunakan dalam penyelidikan 
prostatitis, telah dikaji dalam populasi tempatan. Daripada kajian ini, NIH-CPSI 
didapati memuaskan dari segi validiti dan reliabiliti bagi ukuran simptom pesakit, maka 
adalah sesuai bagi penilaian pesakit dalam kajian di atas. Peralatan urodinamik, iaitu 
U rodesk 3 00 yang mengukur kadar aliran air kencing serta tekanan dalam pundi 
kencing, abdomen dan uretra pula dikaji dari segi ketepatan and kejituannya. Peralatan 
urodinamikjuga didapati sesuai bagi penilaian pesakit dalam kajian di atas. 
Seterusnya, suatu kajian prevalens prostatitis kronik di Pulau Pinang, Malaysia telah 
dijalankan. Daripada 314 7 subjek yang disoalselidik, sebanyak 8. 7% didapati 
menghidap penyakit prostatitis kronik. Penilaian klinikal yang merangkumi 
pemeriksaan fizikal, "ultrasound" and ujian kencing telah dijalankan ke atas subjek 
yang menghidap prostatitis kronik. Dalam penilaian ini, didapati bahawa 75% juga 
XIX 
rncmenuhi kriteria klinikal untuk prostatitis kronik, manakala 25% menghidap penyakit 
lain seperti batu karang ginjal dan varikosil. Hasil soal selidik tersebut juga 
menunjukkan bahawa sebanyak 8.0% daripada subjek yang terlibat mempunyai 
simptom urinari. 
Bagi meningkatkan kefahaman penyakit ini, kajian urodinamik ke atas pesakit-pesakit 
prostatitis kronik telah dijalankan. Sebanyak 41.2% pesakit mempunyai masalah pundi 
kencing, seorang pesakit mempunyai "bladder outlet obstruction" dan seorang pesakit 
mempunyai "detrusor sphincter pseudodyssynergia". Purata kadar a1iran kencing 
~ maksimum didapati lebih rendah manakala "post void residual urine" lebih tinggi 
w.c 
berbanding dengan kumpulan sukarelawan yang sihat. Suatu kaedah analisis 
kromatografi cecair prestasi tinggi juga telah dibangunkan untuk _ menganalisis 
kepekatan terazosin dalam plasma manusia dan seterusnya kajian farmakokinetik 
terazosin telah dijalankan. 
Bahagian terakhir kajian ini melibatkan suatu kajian "randomized double-blind" dengan 
kawalan placebo. Dalam kajian ini, seramai 100 orang pesakit prostatitis kronik, 
berumur antara 20 dan 50 tahun diberikan terazosin atau placebo secara rawak selama 
14 minggu. Keberkesanan terazosin dinilai dengan menggunakan NIH-CPSI. Terazosin 
didapati mengurangkan skor NIH-CPSI lebih banyak (p=0.01) berbanding dengan 
' . 
placebo, iaitu sebanyak 57% berbanding dengan 37%. Terazosin juga mengurangkan 
skor domain individu NIH-CPSI (simptom sakit, urinari dan kesan ke atas kualiti hidup) 
dan "International Prostate Symptom Score" lebih banyak berbanding dengan placebo. 
Daripada keputusan kajian ini, didapati bahawa terazosin lebih berkesan daripada 
placebo untuk rawatan penyakit prostatitis kronik. 
XX 
ABSTRACT 
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is the most common form 
of prostatitis but yet the least understood. There is at present, no evidence based 
thl!rapeutic plan for the management of these patients. Hence, the present study aimed to 
~' 
e C\'aluate the efficacy terazosin, an Ill-blocker for treatment of CP/CPPS. 
Prior to the above study, the National Institutes of Health - Chronic Prostatitis 
Symptom Index (NIH-CPSl), a prostatitis specific index, recommended by the US 
National Institutes of Health for research trials, was evaluated in the local population. 
The NIH-CPSI was demonstrated to have satisfactory reliability and validity as an 
outcome measure and hence found to be suitable for patient asse~sment in the terazosin 
treatment study. The urodynamics equipment, Urodesk 300, on the other hand, was 
validated for its within- and between-day precision and accuracy with respect to the 
urinary flow rate and volume, together with pressure within the bladder, abdomen and 
urethra. The urodynamics equipment was also demonstrated to give reliable outcome 
measures. 
In the next part of the study, the prevalence of CP/CPPS in Penang, Malaysia was 
determined. Of the 3147 subjects surveyed, 8.7% were found to have CP/CPPS. In 
' 
addition, thorough clinical evaluation of those found to have CP/CPPS confirmed that 
75% of subjects who met the survey criteria also met clinical criteria for CP/CPPS. The 
clinical evaluation, which included physical examination, ultrasound and urinalysis 
found that 25% of the patients who met the survey criteria could be excluded due to 
other urological conditions such as urinary stones and varicocele. The survey also 
XXI 
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demonstrated that the prevalence of lower urinary tract symptoms was 8.0% in the 
population studied. 
To achieve a better understanding of this condition, the urodynamic profile ofCP/CPPS 
patients was evaluated. A high proportion (41.2%) of CP/CPPS patients had various 
bladder abnormalities, one each had bladder outlet obstruction and detrusor sphincter 
pseudodyssynergia. Additionally, peak urinary flow rate was significantly lower while 
post void residual urine volume was significantly higher than those of the control group. 
An assay method for determining plasma terazosin levels was also developed and 
~ 
gr~ i subsequently a pharmacokinetic study of terazosin was conducted in the local 
~ 
~ ~ population. 
l E 
ii1 ~· 
In the final part of the study, a randomized double-blind placebo-controlled study was 
conducted. A total of 100 CP/CPPS patients aged 20 to 50 years, were randomized to 
receive either terazosin or placebo for 14 weeks. Treatment efficacy was assessed 
primarily by the NIH-CPSI. Terazosin was found to reduce the NIH-CPSI total score 
(57% reduction) significantly greater (p=O.Ol) than placebo (37% reduction). Ter~osin 
was also effective in reducing the scores of the individual NIH-CPSI domains of pain, 
urinary and quality of life impact as well as the IPSS score when compared to placebo. 
Thus, the present study found that terazosin was more effective than placebo in the 
treatment of patients with CP/CPPS. 
XXll 
CHAPTER 1. INTRODUCTION 
1.1 PROSTATITIS 
1.1.1 INTRODUCTION 
Prostatitis is a major healthcare issue (Nickel et al, 1999a), being the third most 
important prostate disease after prostate cancer and benign prostatic hyperplasia (BPH). 
Unlike prostate cancer and BPH, which usually inflict older men, prostatitis affects men 
of all ages with major economic implications (Calhoun et al, 2001). Patients experience 
a negative impact on their quality of life similar to patients with unstable angina, a 
recent myocardial infarction, or active Crohn's disease (Wenninger et al, 1996). A 
catch-all term to describe an array of symptoms that include pain in various places, 
urinary problems, and sexual dysfunction," prostatitis reflects a lack of knowledge not 
only regarding its origin but also its treatments, that led urologists to call the diagnosis a 
"wastebasket of clinical ignorance" (Vastag, 2001). At present, physicians and 
urologists do not have an evidence-based therapeutic plan for 90% of prostatitis 
patients, when there is no definite microbiological etiology (Collins et al, 2000a). 
1.1.2 DEFINITION OF PROSTATITIS SYNDROMES 
Prostatitis encompasses a heterogeneous group of infectious and non-infectious 
disorders, most of which are not sufficiently evaluated to determine their etiology. The 
diagnostic classification system .for prostatitis syndromes has been updated recently 
from the traditional classification system (Drach et al, 1978). According to the most 
recent classification to date, prostatitis can be divided into four categories as shown in 
Table 1.1. 
1 
Tablcl.l National Institutes of Health Classification ofProstatitis (Nickel et al, 1999a) 
Category Name Description 
Acute bacterial prostatitis Acute infection of the prostate gland 
(ABP) 
ll Chronic bacterial Recurrent unnary tract infection/chronic 
prostatitis (CBP) infection of the prostate 
III Chronic abacterial Discomfort or pain in the pelvic region/variable 
prostatitis/chronic pelvic voiding and sexual symptoms/no demonstrable 
IliA 
IIIB 
IV 
pam syndrome infection 
(CP/CPPS) 
Inflammatory . chronic Excessive number of white cells m 
pelvic pain syndrome semen/EPSNB3 
Non-inflammatory 
chronic pelvic 
syndrome 
Insignificant number 
pam semen/EPSNB3 
of white cells 
Asymptomatic Evidence of inflammatioij 
inflammatory prostatitis biopsy/semen!EPSNB3, no symptoms 
(AlP) 
2 
m 
m 
- - ~ -- -- ---- - - -
. -· ---- ------------------- --· ----------~-----'--· ··-- --- ---·-- -----------
"' The (US) National Institutes of Health recognized the limited understanding of the 
etiology for most patients previously diagnosed with chronic prostatitis and the 
possibility that organs other than the prostate gland may be important in the 
pathogenesis of this syndrome (Nickel et al, 1999a). 
Categories I and II are similar to the traditional classification of acute and chronic 
bacterial prostatitis, respectively. Category III, which is referred to as chronic prostatitis 
(CP) or chronic pelvic pain syndrome (CPPS), consists of two subcategories, namely, 
lilA, which is inflammatory in nature and is known traditionally as non-bacterial 
prostatitis (NBP), and IIIB, which is non-inflammatory in nature, is known as 
prostatodynia. This new category III together with category IV; which is asymptomatic 
prostatitis address the major problems and omissions of the traditional and historic 
classification system (Drach et al, 1978) employed for the past few decades. The new 
classification system is dependent on microscopic and culture evaluation of prostate-
specific specimens (i.e. expressed prostatic fluid, ejaculate, postprostate massage urine, 
and/or prostate biopsy). However, the new classification system still suffers from the 
limitations imposed by an inadequate understanding of the relevance of white blood 
cells, lack of standardization of leukocyte investigation techniques, and lack of 
comparable cutoff points for "elevated numbers", as well as a lack of understanding of 
the true clinical relevance of any microorganisms detected in these specimens (Nickel et 
al, 1999a). 
Bacterial prostatitis is characterized by symptoms of urinary tract infection, positive 
cultures of urine or prostatic secretions, and inflammatory cells in prostatic secretions. 
Acute bacterial prostatitis (ABP) causes intense symptoms, as well as constitutional 
3 
tindings. Chronic bacterial prostatitis (CBP) on the other hand, has a more insidious 
onset with less pronounced prostatic inflammation. In addition, patients have irritative 
or obstructive genitourinary symptoms and relapsing or persistent urinary tract 
infections (Meares, 1992). 
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) occurs in men with no 
history of urinary tract infection and negative bacterial cultures of urine and prostatic 
fluid. The new NIH consensus definition of CP/CPPS recognizes that pain is the main 
symptom (with variable voiding and sexual dysfunction) and is the optimal criterion to 
differentiate patients with CP/CPPS from control patients or patients experiencing other 
genitourinary problems (e.g. benign prostatic hyperplasia). The definition· of CP/CPPS, 
proposed by the 1995 NIH Workshop on Chronic Prostatitis (Nickel et al, 1999a) is 
based on the "presence of genitourinary pain in the absence of uropathogenic bacteria 
detected by standard microbiological methodology". However, it is recognized that 
some patients experience only obstructive and irritative voiding symptoms without pain. 
This syndrome is categorized into inflammatory (based on the presence of leukocytes in 
expressed prostatic secretion, postprostatic massage urine, or semen) or non-
inflammatory (no leukocytes in similar specimens). Asymptomatic inflammatory 
prostatitis (category IV) is a new category that accounts for men with prostatic 
inflammation detected during evaluation of another disorder (Kohnen & Drach, 1979; 
Nickel et al, 1999b). 
Of men referred for symptoms consistent with prostatitis, only about 10% have ABP or 
CBP (De Ia Rossette et al, 1993a). Most of the remainder have CP/CPPS, being the least 
4 
understood category. Thus, much of the present discussion is focused on this category 
of prostatitis. 
t.l.3 EPIDEMIOLOGY OF PROSTATITIS 
Epidemiology is concerned with understanding the distribution and determinants of 
diseases in populations. To discuss the epidemiology of prostatitis effectively, an 
operational definition of prostatitis is essential. Until recently, the epidemiology of 
prostatitis was uncertain and limited by the murkiness inherent in the term "prostatitis" 
discussed previously. Thus, the new NIH classification and definition of prostatitis 
provides uniform definition of prostatitis that will facilitate research in epidemiology. 
In the past 3 years, epidemiological research has determined that prostatitis is a very 
common and important disease. Prostatitis was reported to account for 2 million out-
patient visits per year and 8% of urology visits in the United States (US) (Collins et al, 
1998a). Urologists in the US saw an average of 173 patients with prostatitis per year 
(Moon, 1997). In Canada, urologists saw an average of 260 patients with prostatitis per 
year, one third of whom was newly diagnosed (Nickel et al, 1998). However, these 
studies were retrospective in nature, based on urologist/physician/general practitioner 
visits and without specific criteria for diagnosis of prostatitis. The prevalence rate of 
prostatitis in the general population was estimated to be 5% to 9% (Moon et al, 1997; 
Roberts et al, 1998; Mehik et al, 2000; Nickel et al, 2001a). Unfortunately, the few 
prevalence studies were from single, often tertiary referral centers in North America and 
Western Europe. It is difficult to determine if these observations could be generalized to 
other geographic areas such as Asia. In addition, the available studies are difficult to 
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interpret and compare, partly because, as mentioned above, a uniform definition of 
prostatitis has been lacking until recently. 
t.l.~ ETIOLOGIES AND PATHOGENESIS OF PROSTATITIS 
1.1.4.1 ACUTE BACTERIAL PROSTATITIS 
The most common cause of ABP is infection by gram-negative organisms. Strains of 
Eschericha coli were identified in 80% of infections. Pseudomonas aeruginosa, 
Serratia, Klebsiella, and Proteus were identified in 10% to 15% and enterococci in 5% 
to 10% of infections (Meares, 1992). Commonly, infections are caused by a single 
organism, but occasionally by two or more. Besides enterococci, other gram-positive 
organisms are believed to be commensals of the anterior urethra, which only become 
pathogenic under certain circumstances. Obligate anaerobic bacteria seldom cause 
prostatic infection. Several theories exist for the pathogenesis of bacterial prostatitis. It 
probably evolves from ascending urethral infections or reflux of infected urine into 
prostatic ducts that empty into the posterior urethra (Kirby et al, 1982). Other 
possibilities include invasion by rectal bacteria (by direct extension or lymphogenous 
spread) and hematogenous infection. 
1.1.4.2 CHRONIC BACTERIAL PROSTATITIS 
CBP has the same etiologic organisms as ABP. Its pathogenesis includes stasis of 
' 
refluxed infectious material, with resultant ductal fibrosis and stone formation, thereby, 
promoting chronicity (Doble, 1994). 
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t.I.4.3 CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME 
t' Although CP/CPPS is the most common condition, it remains a condition of uncertain 
1: 
~ etiology and is rarely associated with any other infection in the urinary tract. Although 
r urine cultures are negative, recent studies suggest that the etiology of CP/CPPS may be 
~ of bacterial origin. Krieger et al (1996a) found bacterial DNA in 77% of prostate 
t 
r biopsies in patients who had no evidence of bacteriuria or bacterial prostatitis by 
f 
traditional clinical tests. Specific polymerase chain reaction assays detected Clamydia 
trachoma/is, Mycoplasma hominis and Trichomonas vagina/is in 8% of patients. In a 
follow-up study (Krieger e~ al, 2000), bacterial DNA sequences were found in 19.6% of 
patients with prostatic cancer and 46.4% of patients with CP/CPPS, suggesting that 
DNA sequences may not be specific to CP/CPPS only. Thus, it is clearly premature, as 
the authors pointed out, to conclude that the presence of bacterial DNA sequences are 
associated with prostatitis symptoms. 
Clamydia trachomatis (De la Rossette et al, 1993a; Bruce & Reid, 1989; Polleti et al, 
1985), Ureaplasma urealyticum (Ohkawa et al, 1993), Mycoplasma hominis, and 
Trichomonas vagina/is (Meares, 1992) ~ave been implicated in previous studies. 
However, failure to docwnent an immune response in patients reported to have 
Ureaplasma or Clamydia (Shortliffe et al, 1992; Schachter, 1985), negative results from 
other studies (Berger et al, 1989; Doble et al, 1989), possible problems in identification 
of organisms, and possible ~ethral contamination of samples (Polleti et al, 1985), raise 
questions about the etiologic role of these organisms in CP/CPPS. Gram-positive 
organisms have been suggested (Drach, 1974; Nickel & Costerton, 1992; Lowentrit et 
al, 1995; Berger et al, 1997) but are generally agreed to be commensals rather than 
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pathogens (Anderson & Weller, 1979). Thus, the role of an infectious agent in CP/CPPS 
has not been established. 
Other hypothesized causes of chronic prostatitis include chemical prostatitis resulting 
from intraprostatic urinary reflux (Kirby et al, 1982). Urate appeared to be the chemical 
agent eliciting the inflammatory response (Persson & Ronquist, 1996). An autoimmune 
response (Moon, 1998) and a viral etiology have also been implicated (Doble et al, 
1991 ), but the results of these studies were inconclusive. 
CP/CPPS may result from tension myalgia of the pelvic floor (Sinaki et al, 1977), or an 
increased tension in the muscles ofthe bladder neck and prostatic urethra. Urodynamic 
and neuromuscular studies have provided conflicting results on the pathophysiology of 
CP/CPPS. Some studies have indicated that CP/CPPS is caused by abnormal external 
sphincter activities (striated muscles) (Siroky et al, 1981; Osborn et al, 1981; Hellstrom 
et al, 1987; Zerman et al, 1999; Clemens et al, 2000), whilst others suggested abnormal 
internal sphincter activities or sympathetic dyssynergia (Barbalias et al, 1983; Barbalias, 
1990; De la Rossette et al, 1992; Theodorou et al, 1999). Mayo et al (1999) on the other 
hand, found that only few patients (2%) referred to the Prostatitis Clinic had bladder 
outlet obstruction, suggesting that these patients had neither voiding abnormalities nor 
dyssynergia. 
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t.1.5 CLINICAL FEATURES 
t.I.S.l ACUTE BACTERIAL PROSTATITIS 
ABP typically presents with a sudden onset of fever, chills, general malaise and pain in 
the lower back, rectum, or perineum. Most patients also have intense irritative and 
obstructive genitourinary symptoms. Rectal palpation usually discloses an exquisitely 
' L tender, swollen prostate gland that is partially or totally firm, irregular, and warm to the ~tt' 
~{ 
~ touch. The prostatic expressate is packed with leukocytes and fat-laden macrophages, 
' 
and a large number of the bacterial pathogen grow on culture. Because ABP is usually 
accompanied by bacteriuria, the pathogen generally can be identified by culture of the 
voided urine. 
1.1.5.2 CHRONIC BACTERIAL PROSTATITIS 
CBP often presents with urinary tract infections caused by recognized uropathogens, 
objective evidence of inflanunation, and a prostatic focus of infection (Krieger & 
McGonagle, 1989). CBP is characterized by recurrent urinary tract infections caused by 
the same bacterial species. Patients are often asymptomatic between episodes of 
bacteriuria and seldom have abnormalities on physical examination. Chills and fevers 
are unusual, unless an acute exacerbation of the chronic infection occurs. Some men 
have dysuria or other voiding complaints, ejaculatory pain, hemospermia, or pelvic pain. 
1.1.5.3 CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME 
Inflammatory and non-inflanunatory CP/CPPS produce similar systems. Chronic pelvic 
pains are the most prominent urogenital symptoms of CP/CPPS (Krieger et al, 1996b). 
The most frequent and discriminatory site of pain is perineal (Alexander & Trissel, 
1996; Nickel & Sorensen, 1996). Other sites include suprapubic, testicular, penile, 
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rectal, and lower back. Urinary symptoms are also prevalent and they include urgency, 
[ nocturia, frequency, dysuria, weak urinary stream, hesitancy, post void dribbling and 
i!>~· t interrupted flow. Although pelvic pains seem to be most discriminatory, some patients 
~· experience only irritative and obstructive voiding symptoms, without accompanying 
f pain (Nickel et a, 1999a). Sexual dysfunction may include painful ejaculation, difficulty getting and maintaining erection, difficulty reaching ejaculation, premature ejaculation, ~·· [~ 
(,;. 
lack of interest in sexual activity and hemospermia (Krieger et al, 1996b ). There is no 
i 'i(..c· history of bladder infections. Urogenital physical examination is unremarkable. The 
r 
prostate may be normal, tender or boggy on digital rectal examination, and patients may 
experience tenderness in periprostatic tissues and "tight" anal sphincter on digital rectal 
examination. Uroflow studies afe abnormal in about 30% of cases (De la Rossette et al, 
1993a), whilst cystometry and pressure flow studies yield variable results. 
1.1.6 LABORATORY DIAGNOSIS OF VARIOUS CATEGORIES OF 
PROSTATITIS 
Despite being an important disease, little information is available on the optimal 
approach to its diagnosis (Collins et al, 2000a). ABP is gener~lly recognized easily 
because its clinical manifestations are dramatic and characteristic; in contrast, the 
clinical features of chronic prostatitis syndromes are highly variable and inexact. Indeed 
many signs, symptoms and physical findings in cases of CBP, inflammatory and non-
inflammatory CP/CPPS are often indistinguishable. The medical history and physical 
findings may suggest diagnosis but are not confirmatory. 
Histological examination of prostatic tissue generally is required for diagnosing unusual 
forms of prostatitis such as granulomatous prostatitis. However, the histological changes 
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seen in CBP or CP/CPPS are not sufficiently specific to confirm a diagnosis. Kohnen 
and Drach (1979) reviewed 169 consecutive cases of surgically resected hyperplastic 
prostates and found an incidence of inflammation of about 98%. Nickel et al ( 1999b) 
identified inflammation in all 80 patients with a diagnosis of BPH who underwent 
transurethral resection of the prostate. Clearly, prostatic inflammation is an extremely 
common histological finding in patients with no symptoms of prostatitis and is of 
questionable use in the diagnosis of prostatitis syndromes. 
1.1.6.1 LOWER URINARY TRACT LOCALIZATION STUDIES (4-GLASS TEST) 
The Meares and Stamey (1968) 4-glass test (Appendix 1.1) has been the definitive test 
to differentiate between bacterial from non bacterial,-- and inflammatory from non-
inflammatory prostatitis. It is however, contraindicated in ABP, where it is painful for 
the patient and may cause bacteriemia. This method, called the lower urinary tract 
localization study, is based on comparison of quantitative colony counts from specific 
aliquots of urine specimens obtained before and after prostatic massage (Table 1.2). 
~ Finding at least 10 leukocytes per high power field ( 400X magnification) in prostatic 
i€ 
secretions indicates inflammation (Drach et al, 1978). Anderson and Weller (1979) 
observed a five-fold increase in leukocytes and an eight-fold increase in lipid-laden 
macrophages in expressed prostate secretions of men with NBP compared with control 
subjects. Unfortunately, the lower urinary tract localization study has never been 
properly validated, and few urologists and almost no primary care physicians use it 
routinely in clinical practice (Collins et al, 2000b ). The reasons include its cumbersome 
nature, its low yield, the perception that it results in many false negatives and false 
positives, as well as its poor diagnostic value. 
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Table 1.2 Interpretation of the 4-glass test 
- Test VBl 
specimen 
Cat II WBC 
Culture 
Cat IliA WBC 
Culture 
Cat IIIB WBC 
Culture 
Cat = NIH Classification Category 
WBC = white blood cell 
VB I = first voided urine specimen 
VB2 
+I-
+I-
VB2 = second voided specimen or midstream specimen 
EPS = expressed prostatic secretion 
VB3 = third voided urine or post massage urine 
12 
EPS VB3 
+ + 
+ + 
+ + 
The interpretation of the culture results from the four aliquots collected depends on a 
comparison of the quantitative bacterial counts of the specimens. To clearly document 
cases of urethritis, prostatitis or cystitis, the counts for the appropriate specimens must 
differ by at least one to two orders of magnitude to be considered significant. If the 
count of the first voided urine specimen (VB 1 ), significantly exceeds the count of either 
expressed prostatic secretion (EPS) or post massage urine (VB3), then urethritis or 
significant colonization is present. If the count of either EPS or VB3 significantly 
exceeds VB 1, then bacterial prostatitis is present. If the count of the second voided 
specimen or midstream 'Qrine specimen (VB2), significantly exceeds all other 
specimens, or all four aliquots show heavy growth, then true cystitis or bladder infection 
is present. In this case, the results cannot be interpreted with respect to the presence or 
absence of bacterial prostatitis. Therefore, the patient should be placed on an 
antibacterial regimen (e.g. nitrofurantoin) that will sterilize the bladder urine but which 
is known not to diffuse into the prostatic fluid and the localization study can be repeated 
in four or five days when the bladder urine is sterile. 
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1.1.6.2 POTENTIAL DIAGNOSTIC TESTS OF CP/CPPS 
Alexander et al (1998) found a strong correlation between levels of interleukin-~ and 
tumor necrosis factor-a. in the semen of men with CP/CPPS. This finding suggests that 
seminal proinflammatory cytokines may provide an objective measure of disease in 
these patients. However, the lack of correlation between cytokine levels and the 
leukocyte count in expressed prostatic secretions suggests that cytokine levels do not 
distinguish a meaningful subpopulation of symptomatic patients 
Investigators have hypoth.esized that immunologic analysis may be a better diagnostic 
tool than the lower urinary tract localization study (Meares & Stamey, 1968). Two small 
studies (Wishnow et al, 1982; Shortliffe & Wehner, 1986) suggested that immunologic 
analysis of prostatic fluid for antigen-specific antibodies might aid in the differential 
diagnosis between bacterial and non-bacterial prostatitis. However, neither study 
provided the sensitivity or specificity required. 
Zinc has been examined as a marker of prostatic secretary function. Marmar et al (1980) 
found that zinc levels in men with CP/CPPS and men with bacterial prostatitis were 
significantly lower that those in controls and men with prostatodynia. The investigators 
concluded that measurement of zinc levels might help in the differential diagnosis and 
classification. In contrast, Zaichick et al (1996) found no differences in zinc levels 
among patients with CP/CPPS, BPH and healthy controls. 
Several studies have examined the role of ultrasonography as a diagnostic test for 
CP/CPPS. Doble and Carter (1989) found that seven of eight ultrasonographic signs 
were significantly associated with the presence of symptoms of CP/CPPS compared 
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with controls; sensitivity and specificity were calculated for each sign. Although the 
sensitivity of ultrasonography increased with higher leukocyte counts, the signs were 
not sufficiently specific to different clinical groups. 
In summary, there is no gold standard diagnostic test for CP/CPPS other than the 
standard textbook lower urinary tract localization study ( 4-glass test). The 
methodological quality of the available studies of other diagnostic tests is weak. 
Moreover, the studies used only small sample sizes. 
1.1.7 OUTCOME MEASURES 
1.1.1. 7 PROST A TITS SPECIFIC INDEX 
Prostatitis is a disease in which quantification of symptoms is paramount in following a 
patient's progress. In a disease characterized primarily by symptom complexes, some 
form of symptom assessment instrument is a prerequisite to determine and validate 
criteria for disease categories, to perform epidemiological surveys (i.e. natural history 
and population-based studies), and to evaluate the efficacy of various therapeutic 
interventions. 
Neal and Moon (1994) developed a simple questionnaire (four questions only) that 
appeared helpful for assessing and following patients with CP/CPPS before and after 
' " 
treatment with an alpha-1 blocker. Krieger et al (1996b) developed a 21-question 
symptom questionnaire, which consists of 3 domains namely, pain, urinary and sexual 
dysfunction. Another prostatitis-specific questionnaire, the Symptom Severity Index 
was developed and validated by Nickel and Sorensen (1996). None of the above 
symptom scores was regarded as the gold standard, but the work of these authors 
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pro' ided an important foundation for the development of the National Institutes of 
Health- Chronic Prostatitis Symptom Index (NIH-CPSI) (Litwin et al, 1999). The NIH-
CPS! is a properly validated prostatitis-specific symptom index, which examines the 
main domains of prostatitis such as pain, urinary and quality of life impact. It is a nine-
question questionnaire that is simple, easy and quick to administer and useful in 
research studies and clinical practice. The NIH International Prostatitis Collaborative 
Network (IPCN) suggested that the outcome measures in prostatitis research trials 
should include this index. The NIH-CPSI clearly differentiates CP/CPPS from two 
control populations: patients with no genitourinary symptoms and patients with benign 
prostatic hyperplasia. However, the index has not been assessed in other populations or 
for its sensitivity for determining significant clinical changes. 
1.1.7.2 THE INTERNATIONAL PROSTATE SYMPTOMS SCORE 
The I~ternational Prostate Symptom Score (IPSS) is a commonly used instrument in 
multicenter international clinical trials to assess treatment outcomes in BPH. It consists 
of seven questions related to incomplete voiding, frequency, interrupted stream, 
urgency, weak stream, straining and nocturia, and a disease-specific quality of life 
question (Barry et al, 1992). Each question is rated from 0 ("not at all") to 5 ("almost 
always"). The total IPSS is the sum of items 1-7 (range 0-35) and it assesses the overall 
severity of lower urinary tract symptoms. It has been evaluated for reliability, validity 
and sensitivity to clinical change in BPH, but it was later found that it was not specific 
to the disease. Because patients with CP/CPPS experience similar lower urinary tract 
symptoms such as frequency and urgency (Alexander & Trissel, 1996), the IPSS has 
been used as one of the outcome measures in previous trials even though it has not been 
validated for this purpose. 
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1.1.7.3 UROFLOWMETRY 
Uroflowmetry measures the flow rate of the external urinary stream by volume per unit 
time in ml/s. The urinary flow rate and pattern reflect the final results of the micturition 
process consisting of detrusor function, bladder neck opening and urethral conductivity. 
An abnormal flow rate indicates impaired voiding but does not determine the exact 
location of the suspected dysfunction. The maximum flow rate is the maximum 
measured value of the urine flow rate and is the most important single parameter in 
uroflowmetry. Interpretation of maximum flow rate values requires familiarity with the 
flow curve pattern, the .voided volume, age, sex, artifacts and circadian rhythms. 
Maximum urine flow rate is highly dependent on the volume voided. Detrusor muscle 
when stretched, achieves an optimal performance, but if stretched further, it becomes 
inefficient. Haylen et al (1988) described the maximum flow rate as having a linear 
relationship with square root of voided urine volume, whereas Drach et al (1979) 
suggested that maximum flow rate has a linear relationship with voided volume. 
Abrams (1997) recommended that the volume voided should be in the range of200-500 
mls, and the lowest acceptable flow rate is 21 mlls for males of 14-45 years old. 
However, it is difficult to determine if these values can be generalized to other 
populations. Because it is simple, fast and non-invasive, uroflowmetry is commonly 
used as a screening tool prior to more complicated urodynamic studies, as well as an 
outcome measure in clinical trials including those of BPH and CP/CPPS (De la Rossette 
et al, 1992; Neal & Moon, 1994; Barbalias et al, 1998; Lacquaniti et al, 1998). Flow 
rates should be evaluated not only with consideration of normal values in the population 
of interest, but also with machine reliability. Even though most commercially available 
flowmeters have acceptable accuracy, clinicians should seek independent information 
on the reliability of their machines, both from the standpoint of accuracy and precision. 
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1.1.8 TREATMENT 
1.1.8.1 ACUTE BACTERIAL PROSTATITIS 
ABP is quite easily managed with a wide spectrum of antibiotic coverage (usually 
parenteral) and in many incidences involves some form of lower urinary tract drainage 
(preferably suprapubic tube). Preferred initial therapy in the nonallergic patient is 
trimethoprim-sulfamethoxazole (TMP-SMX). There is evidence that the new 
fluoroquinolone agents such as ciprofloxacin, norfloxacin, ofloxacin, and enoxacin have 
excellent efficacy in the ~reatment of ABP (Meares, 1992). 
1.1.8.2 CHRONIC BACTERIAL PROSTATITIS 
Treatment for CBP usually requires long-term therapy with antibiotics. The class of 
antibiotics that are recommended is the fluoroquinolones. They have an affinity for the 
prostate gland and seem to accumulate well there. Additionally, there is the added 
benefit of a broad spectrum activity, covering the usual and unusual uropathogens in 
addition to some of the more fastidious microorganisms, such as Clamydia, 
Mycoplasma and Ureaplasma species. Most authors agree that four weeks is a 
minimum period of time necessary to eradicate a prostate infection, while others extend 
this to 8-12 weeks (Neal, 1998). 
1.1.8.3 CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME 
CP/CPPS is however, more difficult to treat. In the last 30 years, a multitude of 
treatments for CP/CPPS have been investigated. Some appeared to be successful, but on 
closer examination the studies utilized small sample sizes, were uncontrolled and brief 
with undefined populations and unvalidated outcome measures. To date, there is no 
well-designed placebo-controlled study that provides significant evidence of the 
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dlicacy and safety of any device or treatment in the management of CP/CPPS (Nickel, 
:!000). 
Persson and Ronquist (1996) theorized that backflow of urine into prostatic ducts 
caused prostatic inflammation by increasing concentrations of metabolites that contain 
purine and pyrimidine bases. Subsequently, a double-blind controlled study of 
allopurinol treatment in 54 men was performed (Persson et al, 1996). Although this 
small trial showed improvements in patient-reported symptoms, investigator-graded 
prostate pain as well as biochemical variables, the data provided, the measures used, and 
the statistics presented do not conclusively support the idea that changing the amounts 
of purine and pyrimidine bases in urine and prostatic secretions would relieve the 
symptoms (Nickel et al, 1996). A randomized controlled trial found that compared to 
placebo, quercetine, a naturally occurring bioflavonoid, was well tolerated and produced 
significant improvements in NIH-CPSI symptom scores (Shoskes et al, 1999). 
However, the study only involved 15 patients and the 1-month follow-up period was 
relatively short. Finasteride has been found to reduce symptoms in patients with 
inflammatory CPPS compared to placebo (Leskinen et al, 1999). However, pain ratings 
did not differ significantly between groups. Although the authors speculated that a 
reduction in prostate volume may alleviate symptoms, the mechanism by which 
finasteride would improve symptoms in patients with CP/CPPS remains unknown. 
Prostate massage, which has been employed for decades in the treatment of prostatic 
disorders, has recently seen a resurgence (Nickel et al, 1999c ). The technique of 
repetitive massage, in theory, empties the prostatic ducts of inspissated secretions and 
presumably pockets of infection that may be harboured by obstructed regions of the 
gland (Neal, 1998). This treatment combined with concomitant antibiotic usage, may 
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f ~ afit>rd a treatment alternative for refractory patients (Nickel et al, 1999d). Other 
'' published studies recommended treatments that included pollen extract (Buck et al, 
1989), trice-weekly ejaculation (Yavascaoglu et al, 1999), pentonsan polysulphate 
(Nickel et al, 2000), non steroidal anti-inflammatory medications (Pontari, 1999), 
antibiotics (Nickel et al, 2001 b), and a combination of biofeedback, pelvic floor 
relaxation techniques and bladder training (Clemens et al, 2000). However, none of 
these studies were randomized placebo-controlled. 
The literature also contains many reports of surgical procedures for CP/CPPS such as 
transurethral and "subtotal" prostate resection (Meares, 1986), transurethral incision of 
the prostate (Kaplan et al, 1994 ), and hyperthermia (Servadio & Leib, 1991; Nickel & 
Sorenson, 1994; Nickel & Sorensen, 1996). However, drug therapy is generally 
preferred as the majority of patients are sexually active. 
This wide variety of treatments being investigated, is a reflection of patients' and 
clinicians' frustration with respect to management of CP/CPPS. Therapy is totally 
empirical and ineffective in many cases. In 1998, the International Prostatitis 
Collaborative Network developed a list of treatment modalities that should be evaluated 
in properly designed trials in any future research endeavour. The treatment modalities in 
order of priority are o:utlined in Table 1.3. 
Role of a-1 blockers 
Because symptom complexes of CP/CPPS and BPH o•.rerlap (e.g. frequent urination, 
nocturia, incomplete emptying, urgency, hesitancy, terminal dribbling, intermittency, 
weak stream), investigators have hypothesized that drug therapy for BPH may help 
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Table 1.3 Prioritizations* of treatments for chronic prostatitis/chronic pelvic pain 
syndrome (Nickel et al, 1999a) 
Treatment Category 
Antimicrobials (e.g. antibiotics) 
Alpha-blockers (e.g. terazosin) 
Prostatic massage (repetitive) 
Anti -inflammatories (NSAIDS, hydroxyzine) 
Pain control measures (e.g. gabapentine, tizanidine) 
Biofeedback (e.g. perineal) 
Phytotherapy (e.g. saw palmetto, quercetine) 
Alpha-reductase inhibitors (e.g. finasteride) 
tvluscle relaxants (e.g. diazepam, baclofen) 
Devices (TUMT, TUNA, laser) 
Physical therapy (massage therapy, air rings/donuts 
Psychotherapy 
Alternate therapy (e.g. meditation, copmg skills, 
acupuncture 
Heparinoids (e.g. pentonsan polysulfate) 
Capsaisin 
Allopurinol 
Surgery (TURBN, TURP, radical prostatectomy) 
Rank 
2 
3 
3 
4 
5 
6 
7 
8 
9 
10 
10 
11 
12 
12 
13 
13 
Priority rating 
(mean score) 
4.4 
3.7 
3.3 
3.3 
3.1 
2.7 
2.5 
2.5 
2.4 
2.2 
2.1 
2.1 
2.0 
1.8 
1.8 
1.5 
1.5 
NSAIDs = non-steroidal anti-inflammatory drugs; TUMT = transurethral microwave 
thermotherapy; TUNA = transurethral needle ablation; TURBN = transurethral 
resection of bladder neck; TURP =transurethral resection of prostate. 
*Priority rating: 5, highest; 4, high; 3, medium; 2, low; and 1, very low 
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some men with CP/CPPS. Alpha-1 blockers are the most widely used drugs in the 
medical management ofBPH and have been investigated for the treatment ofCP/CPPS. 
Bladder outlet obstruction (BOO) associated with BPH not only results from 
nonmalignant enlargement of the prostate caused by increased cellular groWth of the 
glandular and stromal components of the gland, but also from the dynamic component 
of the disease, which is alpha-1 receptor mediated increased smooth muscle tone of the 
bladder neck and prostate. Physiologic and pharmacological studies provide compelling 
evidence that the tension_ of human prostatic smooth muscles contributes to BOO. Raz et 
a! (1992) were among the first investigators to study the physiology and pharmacology 
of prostatic· smooth muscles. Isometric tension studies demonstrated that the rat prostate 
contracts in the presence of norepinephrine, an adrenergic agonist. Caine et al (1975) 
subsequently demonstrated that the human prostate adenoma and capsule also contract 
with the presence of norepinephrine. Caine et al (1976) recognized the therapeutic 
implications of pharmacologically altering the tension of prostatic smooth muscles in 
males with clinical symptoms of BPH. By blocking sympathetic input on the alpha-1 
adrenergic receptor, alpha-1 blockers aim to relax the smooth muscles in the prostate, 
its capsule, and the area around the bladder neck, and by this mechanism, improve 
urinary flow. This, in turn, relieves both irritative and obstructive symptoms of the 
lower urinary tract. 
Video-urodynamic studies have suggested that CP/CPPS symptoms could be attributed 
to functional/dynamic obstruction at the bladder neck. This was evidenced by narrowing 
of the bladder neck during voiding, with complete absence of electromyographic 
activity (complete relaxation of the striated urethral sphincter). A sympathetically 
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mediated contraction of the bladder neck during voiding was thus suggested as the 
pathophysiology of this condition, and hence alpha-blockers were postulated to be 
bl!neficial to these patients (De Ia Rossette, 1992; Barbalias et al, 1983; Barbalias 1990; 
Theodorou et al, 1999). Moreover, it has been shown that dysfunctional voiding may 
result in reflux of urine into the prostatic ducts, creating a sterile inflammatory process. 
If the urine is infected, prostatitis may ensue by the reflux of bacteria into the prostatic 
acinar system (Hellstrom et al, 1987). Furthermore, a study by Y amanashi et al (2000), 
found that terazosin was effective in opening the bladder neck and improving hydraulic 
energy profile in men with bladder neck obstruction. a-1 blockers, therefore may 
ameliorate prostatitis symptoms whether infectious or not, by reducing the degree of 
dysfunctional voiding that may be primarY or secondary in the pathogenesis. In fact, 
several studies have shown that a-blockers improved symptoms in CP/CPPS (Osborn et 
al, 1981; De la Rossette et al, 1992; Neal & Moon, 1994; Barbalias et al, 1998; 
Lacquaniti et al, 1998). However, only two of these studies (De la Rossette et al, 1992; 
Lacquaniti et al, 1998) were randomized placebo-controlled, of which only the study by 
Lacquaniti et al (1998) used a validated symptom score for CP/CPPS. The study by 
Neal and Moon (1994), also used a validated score for CP/CPPS, but the study was not 
randomized placebo-controlled. More importantly, none of the studies employed the 
new NIH consensus definition for CP/CPPS, which recognizes pain as the predominant 
symptom. 
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1.2 TERAZOSIN 
1.2.1 CHEMISTRY 
Terazosin, an alpha-1-selective adrenoceptor-blocking agent, is a quinazoline derivative, 
represented by the following chemical and structural formula:· 6,7-demethoxy-2-
[ 4(tetrahydrofuran-2-carbonyl)piperazin-1-yl]-quinazolin-4-ylamine. It is the oldest 
selective alpha- I blocker and used widely for the treatment of hypertension and BPH. 
1.2.2 PHARMACOLOGY 
Receptor binding studies have demonstrated that terazosin is highly se1ective for a-1 
receptor (Achari & Laddu, 1992). Terazosin selectively blocks postsynaptic a-1 receptor 
without affecting the presynaptic a-2 receptor. By blocking the a-1 receptor located in 
vascular smooth muscles, terazosin causes them to relax. This in turn decreases 
peripheral vascular resist~ce, resulting in a reduction in blood pressure. Due to its 
selectivity for postsynaptic a-1 receptor, there is minimal reflex increase in heart rate 
during terazosin therapy. In BPH, as well as in CP/CPPS, there is thought to be a-1 
receptor mediated increased smooth muscle tone of the bladder neck and prostate. 
Through blocking the a-1 receptor, terazosin will help to improve urinary flow. 
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